Predictive Oncology (POAI) Corporate Media Kit

Investor Overview D Partnership to improve clinical decision making for ovarian cancer patients meets growing unmet needs, where, each year, more than 22,000 women are diagnosed in the U.S. D Development agreement for diagnostic and assessment prod- ucts targets thyroid cancer treatment market expected to reach $2.1 billion by 2025. D Collaborative research agreement seeks to expand personalized medicine to prostate cancer diagnosis and treatment. D TumorGenesis and 48Hour Discovery awarded the Alberta Innovates grant for development of novel cancer treatments. D New approach to laboratory-grown tumors that simulates nat- ural response to identify cancer biomarkers and assists in rapid approach to development of patient-specific treatment options. D Leverages artificial intelligence and the largest database of its kind with comprehensive historic data and outcomes for multiple types of cancer to assist in a individualized treatment approach. D Patient-derived tumor models, genomic, proteomic and bio- chemical assays and AI-driven models to drive the development of new precision therapies and patient-specific treatment plans. D STREAMWAY machine solution targets the estimated $100 bil- lion Indian healthcare industry and more than $6 billion medical device industry.